FGF21 and metabolic dysfunction-associated steatotic liver disease: Hepatic expression and circulating concentrations of Fgf21 are increased in mice and humans during the onset of obesity and NAFLD (28, 29, 30), suggesting a protective mechanism that is ultimately overwhelmed by sustained overnutrition.